New research from Tokyo, Japan could help clarify the role of proinflammatory mediators in the pathogenesis of chronic inflammatory myopathies, such as polymyositis and dermatomyositis.

ULSCs is under clinical development by RESTEM and currently in Phase I for Dermatomyositis. According to GlobalData, Phase I drugs for Dermatomyositis have a 91% phase transition success rate (PTSR) ...

YTS-109 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Polymyositis.

Medically reviewed by Dale Garber, MDJuvenile myositis (JM) affects those under the age of 18 years. JM is known for causing ...

Regrettably, deceptive situations occur where rheumatology specialists treat patients suffering from symptoms that resemble rheumatic diseases. In reality, the patients may be battling an undiagnosed ...

Keep abreast with the latest news related to Polymyositis there are 13 news items on Polymyositis that covers updates, breakthroughs and in-depth reports. We provide you with a free downloadable ...

These investigators explored how knowing the distinctive features of dermatomyositis in Black adults, which may be subtle, could possibly lead to faster and more accurate diagnosis. To tackle the ...

CORONA, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune ...

L, a lead ULSC program, following the recent Orphan Drug Designation • Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use ...

- Oral presentation at ACR highlights safety and efficacy data from the Phase 1 trial of umbilical cord outer lining-derived stem cells (ULSCs) in patients with ...